Solid Cancer
Center for Cancer Research details research in solid cancer
Published in Angiogenesis Weekly, July 9th, 2010
New research, 'A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors,' is the subject of a report. "Carboxyamido-triazole (CAI) is a calcium influx inhibitor with anti-angiogenic and anti-invasive properties and stabilizes tumor progression in patients. We hypothesized daily oral micronized CAI with q3 week paclitaxel would be well-tolerated and active," scientists in the United States report.
"Twenty-nine heavily pretreated patients [median 3 [0-7] ] were enrolled on five dose levels. No additive or cumulative toxicity was observed, and grade III nonhematological toxicity was rare. Neutropenia was the most common hematologic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
Source: Angiogenesis Weekly (2010-07-09)
More Articles from Angiogenesis Weekly
- Endocrine Cells
Scientists at Osaka Medical College publish new data on endocrine cells - Immunoglobulins
Reports summarize immunoglobulins research from K.C. Wang and co-authors - Angiogenesis
Research from University of Turin provides new data about angiogenesis - Intercellular Signaling Peptides and Proteins
Report summarizes intercellular signaling peptides and proteins study findings from S. Litwin and co-researchers - Angiogenesis
Data on angiogenesis detailed by researchers at Konkuk University, Department of Veterinary Pathology - C Reactive Protein
Data on C Reactive Protein published by researchers at University College, Department of Internal Medicine - More from this issue of Angiogenesis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
